tiprankstipranks
Trending News
More News >
Ramm Pharma Corp (TSE:RAMM)
:RAMM
Canadian Market
Advertisement

Ramm Pharma (RAMM) AI Stock Analysis

Compare
1 Followers

Top Page

TSE:RAMM

Ramm Pharma

(RAMM)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
Ramm Pharma's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and cash flow issues. While technical indicators suggest some positive momentum, the high volatility and negative valuation metrics further weigh down the score.

Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)

Ramm Pharma Business Overview & Revenue Model

Company DescriptionRAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
How the Company Makes MoneyRamm Pharma generates revenue primarily through the sales of its proprietary drug products and formulations. The company also benefits from licensing agreements with larger pharmaceutical firms, wherein it licenses its technology or product candidates in exchange for upfront payments, royalties, and milestone payments based on the progression of the drug through various stages of development. Additionally, Ramm Pharma may engage in partnerships for collaborative research and development projects, allowing it to share costs and tap into the distribution networks of established partners, thereby expanding its market reach and revenue potential.

Ramm Pharma Financial Statement Overview

Summary
Ramm Pharma is facing significant financial difficulties. The company struggles with operational losses and cash flow constraints, as evidenced by a negative net income of -$13.7M and negative free cash flow. Despite a solid equity position with low debt, the ongoing losses and liquidity challenges present substantial risks.
Income Statement
35
Negative
Ramm Pharma's income statement reveals significant challenges. The TTM data shows a negative net income of -$13.7M, indicating substantial losses. The gross profit margin is approximately 36.8%, which is decent but overshadowed by negative EBIT and EBITDA margins, suggesting operational inefficiencies. Revenue has decreased from the previous period, indicating a contraction in sales growth. Overall, the company struggles with maintaining profitability and growth.
Balance Sheet
50
Neutral
The balance sheet shows a relatively strong equity position with stockholders' equity making up over 81.9% of total assets. The debt-to-equity ratio is very low at 0.0034, indicating limited reliance on debt. However, the company faces liquidity challenges with a shrinking cash position. While the low leverage is a strength, the declining asset base and equity value pose risks.
Cash Flow
30
Negative
Ramm Pharma's cash flow statement highlights cash management issues. The company has a negative free cash flow of -$2.5M in the TTM, showing a high cash burn rate. The operating cash flow to net income ratio is negative, reflecting poor cash generation from operations. Overall, the company faces substantial cash flow challenges, impacting its ability to invest and sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.34M5.07M3.90M4.12M5.44M
Gross Profit1.76M381.82K530.50K-7.64K1.28M
EBITDA-15.23M-6.30M-19.91M-6.36M-6.91M
Net Income-16.50M-7.72M-20.96M-7.11M-7.43M
Balance Sheet
Total Assets16.75M32.30M39.31M59.71M37.17M
Cash, Cash Equivalents and Short-Term Investments814.04K5.12M9.77M17.16M28.01M
Total Debt188.31K405.14K683.70K32.16K100.43K
Total Liabilities3.11M2.84M3.72M3.32M1.34M
Stockholders Equity13.63M29.46M35.59M56.39M35.84M
Cash Flow
Free Cash Flow-4.05M-4.45M-6.08M-4.25M-4.80M
Operating Cash Flow-4.00M-4.34M-5.91M-3.82M-2.91M
Investing Cash Flow-47.43K126.58K-1.15M-6.83M-1.56M
Financing Cash Flow-258.23K-409.97K-353.77K-190.33K-2.91M

Ramm Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.02
Price Trends
50DMA
0.01
Positive
100DMA
0.01
Positive
200DMA
0.02
Positive
Market Momentum
MACD
<0.01
Negative
RSI
66.24
Neutral
STOCH
200.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.24 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
C$1.79M-69.77%-15.51%-49.26%
39
Underperform
C$881.12K-36.47%34.50%
29
Underperform
C$1.08M98.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:RAMM
Ramm Pharma
0.02
0.01
100.00%
TSE:PHRX
Pharmadrug
0.01
-0.01
-50.00%
TSE:TCAN
TransCanna Holdings Inc
0.01
0.00
0.00%
TSE:OVAT
Ovation Science
0.04
0.01
40.00%
TSE:NLV
New Leaf Ventures
0.05
0.00
0.00%

Ramm Pharma Corporate Events

M&A TransactionsBusiness Operations and Strategy
RAMM Pharma Explores Sale of Italian Subsidiary Canapar
Neutral
Jan 21, 2025

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 08, 2025